Atlas Trials

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Clinical trial NCT04964479 · UNKNOWN

Trial details

NCT number
NCT04964479
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2021-08-06
Primary completion
2022-12-01
Enrollment
375

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.